Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1201 to 1215 of 2208 results for guidelines

  1. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

    Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.

  2. Deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults (IPG693)

    Evidence-based recommendations on deep brain stimulation for chronic, severe, treatment-resistant obsessive-compulsive disorder in adults. This involves implanting an electrode in the brain and an electrical stimulator under the skin on the chest.

  3. Digital technologies for managing non-specific low back pain: early value assessment (HTG712)

    Early value assessment (EVA) guidance on digital technologies for managing non-specific low back pain in people 16 years and over.

  4. Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (IPG656)

    Evidence-based recommendations on transurethral laser ablation for recurrent non-muscle-invasive bladder cancer in adults. This involves using a laser inserted into the bladder to destroy the cancer cells.

  5. Technology appraisal committees

    Membership details, terms of reference, future meeting dates and past meeting minutes for our 4 technology appraisal committees.

  6. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

  7. Decreasing pharmacological treatment:- In adults, young people and children with well-controlled asthma, what are the objective measurements and prognostic factors that indicate that a decrease in regular maintenance treatment is appropriate?

    applicable) Why this is important:- There is consensus within the guideline committee and across healthcare professionals managing...

  8. Lung texture analysis for measuring interstitial lung diseases (MIB272)

    NICE has developed a medtech innovation briefing (MIB) on lung texture analysis for measuring interstitial lung diseases .

  9. Patient Status Engine for wireless monitoring of vital signs (MIB271)

    NICE has developed a medtech innovation briefing (MIB) on the Patient Status Engine for wireless monitoring of vital signs .

  10. Chief executive's end of year message

    Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.

  11. Omalizumab for previously treated chronic spontaneous urticaria (TA339)

    Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.

  12. Sparsentan for treating primary IgA nephropathy (TA1074)

    Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.

  13. Percutaneous transluminal renal sympathetic denervation for resistant hypertension (IPG754)

    Evidence-based recommendations on percutaneous transluminal renal sympathetic denervation for resistant hypertension. This involves inserting a device through the skin (percutaneous) into an artery in the thigh and then into the renal arteries (transluminal). It sends radio or sound waves to destroy the nerves in the renal arteries (sympathetic denervation). The aim is to lower blood pressure.

  14. Transcutaneous stimulation of the cervical branch of the vagus nerve for cluster headache and migraine (IPG552)

    Evidence-based recommendations on transcutaneous stimulation of the cervical branch of the vagus nerve to treat cluster headache and migraine in adults. This involves using a small handheld device to stimulate a nerve in the neck.